New pill shows promise against rare tumor disorder
NCT ID NCT07131722
First seen Jan 26, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This early-stage trial tests an experimental drug called PRG-N-01 in 25 adults with neurofibromatosis type II (NF2), a genetic condition that causes non-cancerous tumors. The study aims to find the safest and most effective dose, and to see if the drug can shrink tumors and improve hearing and quality of life. Participants will take the drug daily for 96 weeks and have regular checkups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE II are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.